Trial Profile
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Patients With Active Ankylosing Spondylitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Netakimab (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Acronyms ASTERA
- Sponsors Biocad
- 17 Feb 2023 Planned End Date changed from 1 Mar 2022 to 5 Apr 2023.
- 31 Aug 2022 Results of post-hoc analysis assessing response to netakimab in radiographic axial spondyloarthritis patients, published in the Clinical and Experimental Rheumatology.
- 05 Jun 2021 Results of sub-analysis from the ASTERA (NCT03447704) study(n=113) assessing changes in AS activity in pts with and without sacroiliitis on MRI at week 16 of NTK treatment presented at the 22nd Annual Congress of the European League Against Rheumatism